{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:33:17Z","timestamp":1772155997088,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Interest exists concerning the use of angiotensin-converting enzyme inhibitors (ACEis) in patients with COVID-19 disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of the study was to perform a systematic review on mortality associated to the use of ACEi in patients with COVID-19 disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Search in Medline (PubMed), in ISI Web of Knowledge and in medRxiv database; use of other sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 33 articles were evaluated. Concerning the papers used to produce the meta-analyses, 7 studies were selected, 5 of which were used. These 5 studies involved a total number of 944 patients treated with ACEi and 5173 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of COVID-19 disease (ACEi users vs nonusers; odds ratio, 1.48; 95% confidence interval, 1.02\u20132.15;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.04). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.96; 95% confidence interval, 0.76\u20131.21;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.74). Concerning the remaining reports, different types of data adjustments were used by several authors, after which increased mortality was not seen in association to the use of ACEi in this context.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ACEi use could act as a marker of increased mortality risk in some but not all COVID-19 disease settings. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in COVID-19 patients, to establish the safety of ACEi use in this context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000085","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T15:02:48Z","timestamp":1605106968000},"page":"e085","source":"Crossref","is-referenced-by-count":11,"title":["Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review"],"prefix":"10.1097","volume":"5","author":[{"given":"Jos\u00e9 Pedro L.","family":"Nunes","sequence":"first","affiliation":[{"name":"Faculdade de Medicina, Universidade do Porto"},{"name":"Department of Cardiology, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, Porto, Portugal."}]}],"member":"276","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"R1-20231106","doi-asserted-by":"crossref","first-page":"271.e8","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"R2-20231106","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/liv.13861","article-title":"Acute liver failure caused by hepatitis E virus genotype 3 and 4: a systematic review and pooled analysis","volume":"38","author":"Haffar","year":"2018","journal-title":"Liver Int."},{"key":"R3-20231106","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"R4-20231106","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study","author":"Jung","year":"2020","journal-title":"Clin Infect Dis."},{"key":"R5-20231106","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA."},{"key":"R6-20231106","article-title":"Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy","author":"Giorgi Rossi","year":"2020","journal-title":"medRxiv."},{"key":"R7-20231106","first-page":"1","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"23","author":"Li","year":"2020","journal-title":"JAMA Cardiol."},{"key":"R8-20231106","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives","author":"Felice","year":"2020","journal-title":"Am J Hypertens."},{"key":"R9-20231106","doi-asserted-by":"crossref","first-page":"e0235248","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens","volume":"15","author":"Bravi","year":"2020","journal-title":"PLoS One."},{"key":"R10-20231106","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severities: a multicenter study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"R11-20231106","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med."},{"key":"R12-20231106","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res."},{"key":"R13-20231106","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1161\/HYPERTENSIONAHA.120.15622","article-title":"Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality","volume":"76","author":"Zhou","year":"2020","journal-title":"Hypertension."},{"key":"R14-20231106","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"ACE-inhibitors and angiotensin-2 receptor blockers are not associated with severe SARS-COVID19 infection in a multi-site UK Acute Hospital Trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"R15-20231106","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med."},{"key":"R16-20231106","article-title":"Hypertension and renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","author":"Ip","year":"2020","journal-title":"medRxiv."},{"key":"R17-20231106","doi-asserted-by":"crossref","first-page":"m1996","DOI":"10.1136\/bmj.m1996","article-title":"Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series","volume":"369","author":"Argenziano","year":"2020","journal-title":"BMJ."},{"key":"R18-20231106","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med."},{"key":"R19-20231106","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera","year":"2020","journal-title":"medRxiv."},{"key":"R20-20231106","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018\u200aESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J."},{"key":"R21-20231106","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet."},{"key":"R22-20231106","doi-asserted-by":"crossref","first-page":"367","DOI":"10.14336\/AD.2018.0324","article-title":"Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept","volume":"10","author":"Chung","year":"2019","journal-title":"Aging Dis."},{"key":"R23-20231106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"R24-20231106","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMe2012924","article-title":"Inhibitors of the renin\u2013angiotensin\u2013aldosterone system and COVID-19","volume":"392","author":"Jarcho","year":"2020","journal-title":"N Engl J Med."}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T21:03:42Z","timestamp":1699218222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000085","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.29.20116483","asserted-by":"object"}]},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}